Synthesis of daidzein derivatives and their binding affinities to estrogen receptor

Journal of China Pharmaceutical University

Volumn 37, Issue 1, 2006, Pages 23-27

  Xiang, Hua ^a   Fang, Wei ^a   He, Ling ^a   Zhang, Lu Yong ^a   Liao, Qing Jiang ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Binding affinity; Daidzein derivatives; Estrogen receptor; Synthesis

Indexed keywords

CHROMONE DERIVATIVE; DAIDZEIN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; RALOXIFENE; RECEPTOR SUBTYPE;

ARTICLE; BINDING COMPETITION; DRUG DESIGN; DRUG DETERMINATION; DRUG SYNTHESIS; IC 50; INFRARED SPECTROSCOPY; MASS SPECTROMETRY; PROTON NUCLEAR MAGNETIC RESONANCE; RECEPTOR AFFINITY;

EID: 33644513390     PISSN: 10005048     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Haskell SG. Selective estrogen receptor modulators[J]. South Med J, 2003,96(5):469-476.
2. Gajdos C, Jordan VC. Selective estrogen receptor modulators as a new therapeutic drug group: concept to reality in a decade[J]. Clin Breast Cancer, 2002,2(4):272-281.
3. McDonnell DP, Wijayaratne A, Chang CY, et al. Elucidation of the molecular mechanism of action of selective estrogen receptor modulators[J]. Am J Cardiol, 2002,90(1A):35F-43F.
4. van der Mooren MJ, Kenemans P. Postmenopausal hormone therapy: impact on menopause-related symptoms, chronic disease and quality of life[J]. Drugs, 2004,64(8):821-836.
5. Raloxifene hydrochloride[J]. Drugs Fut, 2000,25(7):764-767.
6. Clemett D, Spencer CM. Raloxifene: a review of its use in post-menopausal osteoporosis[J]. Drugs, 2000,60(2):379-411.
7. Jones CD, Jevnikar MG, Pike AJ, et al. Antiestrogen. 2.Structure-activity studies in a series of 3-aroyl-2-arylbenzo [b] thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl) benzo [b] thien-3-yl] [4-[2-(1-piperidinyl) ethoxy]-phenyl] methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity[J]. J Med Chem, 1984,27 (8):1057-1066.
8. Jordan VC. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents[J]. J Med Chem, 2003,46(7):1081-1111.
9. Petilli M, Fiorelli G, Benvenuti S, et al. Interactions between ipriflavone and the estrogen receptor[J]. Calcif Tissue Int, 1995,56 (2):160-165.
10. Brzozowski AM, Pike AC, Dauter Z, et al. Molecular basic of agonism and antagonism in the oestrogen receptor[J]. Nature, 1997, 389 (6652):753-758.
11. Kuiper GG, Carlsson B, Grandien K, et al. Comparision of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta[J]. Endocrinology, 1997, 138(3):863-870.
12. Kuiper GG, Lemmen JG, Carlsson B, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta [J]. Endocrinology, 1998,139(10):4252-4263.
13. Wähälä K, Hase TA. Expedient synthesis of polyhydroxy isoflavones [J]. J Chem Soc Perkin Trans 1, 1991,12:3005-3008.
14. (Ji QE), (Wei YL). Chinese source. (Acta Pharm Sin), 1989,24:906-912.
15. Pelter A, Foot S. A new convenient synthesis of isoflavones[J]. Synthesis, 1976,1976(5):326.
16. Pietro P. Some N-dialkylaminoethyl derivatives of piperidine[J]. Ann Chim Farm, 1938,1:63-70.
17. Wright JB, Lincoln EH, Heinzelmann RV, et al. Histamine antagonist. VII. Phenothiazine derivatives[J]. J Am Chem Soc, 1950,72(8):3536-3539.